The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review

References

• de Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013; 16:203–4
   PubMed Web of Science ®Google Scholar
• Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012;8:CD000402
   Google Scholar
• Mirena® Product Monograph. Bayer HealthCare, 2012. Available at: http://www.mirena.com/html/pdf/Mirena_Product-Monograph_low-res_20120223_670.pdf. Last accessed 22 May 2014
   Google Scholar
• Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002;57:120–8
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Routes of delivery for progesterone and progestins. Maturitas 2007;57:77–80
   PubMed Web of Science ®Google Scholar
• Allen RH, Cwiak CA, Kaunitz AM. Contraception in women over 40 years of age. CMAJ 2013;185:565–73
   PubMed Web of Science ®Google Scholar
• Baldwin MK, Jensen JT. Contraception during the perimenopause. Maturitas 2013;76:235–42
   PubMed Web of Science ®Google Scholar
• Long ME, Faubion SS, Maclaughlin KL, et al. Contraception and hormonal management in the perimenopause. J Womens Health (Larchmt) 2014 April 28. Epub ahead of print
   PubMed Web of Science ®Google Scholar
• US Selected Practice Recommendations for Contraceptive Use, 2013. US Department of Health and Human Services Centers for Disease Control and Prevention, 2013. Available at: http://www.cdc.gov/mmwr/pdf/rr/rr6205.pdf. Last accessed 21 May 2014
   Google Scholar
• Hale GE, Manconi F, Luscombe G, Fraser IS. Quantitative measurements of menstrual blood loss in ovulatory and anovulatory cycles in middle- and late-reproductive age and the menopausal transition. Obstet Gynecol 2010;115:249–56
   PubMed Web of Science ®Google Scholar
• Hickey M, Ambekar M. Abnormal bleeding in postmenopausal hormone users – What do we know today? Maturitas 2009;63: 45–50
   PubMed Web of Science ®Google Scholar
• Antoniou G, Kalogirou D, Karakitsos P, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Maturitas 1997;26:103–11
   PubMed Web of Science ®Google Scholar
• Kalogirou D, Antoniou G, Karakitsos P, et al. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response. Int J Fertil Menopausal Stud 1996; 41:522–7
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Kauppila A. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil Steril 1999;72:161–3
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Malinen H, Sundstrom H, et al. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 1998;77:758–63
   PubMed Web of Science ®Google Scholar
• Ewies AA, Alfhaily F. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstet Gynecol Surv 2012;67:726–33
   PubMed Web of Science ®Google Scholar
• Somboonporn W, Panna S, Temtanakitpaisan T, et al. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011;18:1060–6
   PubMed Web of Science ®Google Scholar
• Raudaskoski T, Tapanainen J, Tomas E, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Bjog 2002;109:136–44
   PubMed Web of Science ®Google Scholar
• Suhonen SP, Holmstrom T, Allonen HO, Lahteenmaki P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995; 63:336–42
   PubMed Web of Science ®Google Scholar
• Suhonen S, Haukkamaa M, Holmstrom T, et al. Endometrial response to hormone replacement therapy as assessed by expression of insulin-like growth factor-binding protein-1 in the endometrium. Fertil Steril 1996;65:776–82
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Sundstrom H, Penttinen J, et al. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 1995;22:255–62
   PubMed Web of Science ®Google Scholar
• Hampton NR, Rees MC, Lowe DG, et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005;20:2653–60
   PubMed Web of Science ®Google Scholar
• Kupperman HS, Blatt MH, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953;13: 688–703
   PubMed Web of Science ®Google Scholar
• Kupperman HS, Wetchler BB, Blatt MH. Contemporary therapy of the menopausal syndrome. J Am Med Assoc 1959;171:1627–37
   PubMed Web of Science ®Google Scholar
• Raudaskoski TH, Lahti EI, Kauppila AJ, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114–19
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Sundstrom H, Penttinen J, et al. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas 1997;26:211–17
   PubMed Web of Science ®Google Scholar
• Pirimoglu ZM, Ozyapi AG, Kars B, et al. Comparing the effects of intrauterine progestin system and oral progestin on health-related quality of life and Kupperman index in hormone replacement therapy. J Obstet Gynaecol Res 2011;37:1376–81
   PubMed Web of Science ®Google Scholar
• Depypere HT, Hillard T, Erkkola R, et al. A 60-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause. Eur J Obstet Gynecol Reprod Biol 2010;153:176–80
   PubMed Web of Science ®Google Scholar
• Suhonen S, Holmstrom T, Lahteenmaki P. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997;76:145–50
   PubMed Web of Science ®Google Scholar
• Boon J, Scholten PC, Oldenhave A, Heintz AP. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. Maturitas 2003;46:69–77
   PubMed Web of Science ®Google Scholar
• Merz E, Miric-Tesanic D, Bahlmann F, et al. Sonographic size of uterus and ovaries in pre- and postmenopausal women. Ultrasound Obstet Gynecol 1996;7:38–42
   PubMed Web of Science ®Google Scholar
• Sokalska A, Valentin L. Changes in ultrasound morphology of the uterus and ovaries during the menopausal transition and early postmenopause: a 4-year longitudinal study. Ultrasound Obstet Gynecol 2008;31:210–17
   PubMed Web of Science ®Google Scholar
• Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969–73
   PubMed Web of Science ®Google Scholar
• Raudaskoski TH, Tomas EI, Paakkari IA, et al. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. Maturitas 1995;22:47–53
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Kauppila A. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol. Arch Gynecol Obstet 1998; 261:201–8
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006;4:1259–65
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–32
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ 2012;344:e2990
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Boulman N, Leiba R, et al. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scand J Clin Lab Invest 2007;67:257–63
   PubMed Web of Science ®Google Scholar
• Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 2010;126:483–9
   PubMed Web of Science ®Google Scholar
• Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011;83:211–17
   PubMed Web of Science ®Google Scholar
• Koskela-Niska V, Pukkala E, Lyytinen H, et al. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer – a population-based case control study from Finland. Int J Cancer 2013;133:1680–8
   PubMed Web of Science ®Google Scholar
• Jaakkola S, Lyytinen HK, Dyba T, et al. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer 2011;128:1644–51
   PubMed Web of Science ®Google Scholar
• Soini T, Hurskainen R, Grenman S, et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014;124:292–9
   PubMed Web of Science ®Google Scholar
• Hunter MS. The Women’s Health Questionnaire (WHQ): Frequently asked questions (FAQ). Health Qual Life Outcomes 2003;1:41
   PubMedGoogle Scholar
• Kailasam C, Cahill D. Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system. Patient Prefer Adherence 2008;2:293–302
   PubMedGoogle Scholar
• Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol 2013;122:1205–13
   PubMed Web of Science ®Google Scholar
• Suhonen SP, Allonen HO, Lahteenmaki P. Sustained-release subdermal estradiol implants: a new alternative in estrogen replacement therapy. Am J Obstet Gynecol 1993;169:1248–54
   PubMed Web of Science ®Google Scholar
• Suhonen SP, Allonen HO, Lahteenmaki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995; 172:562–7
   PubMed Web of Science ®Google Scholar
• Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel – a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963–7
   PubMed Web of Science ®Google Scholar